Hematopoietic Cell Transplantation for Chronic Myelogenous Leukemia
Customize your policy alerts
Sign up for Aetna Policy 0674 alerts
Get alerted when Policy 0674 changes without checking for updates manually.
Monitor payer policy activity
Defines Aetna's coverage stance for hematopoietic cell transplantation (HCT) in members with chronic myelogenous leukemia (CML), including medical necessity criteria for allogeneic transplants and the noncoverage stance for autologous transplants. Applies to patients being considered for HCT for CML.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.